NCCM
ALDR

Nine Chapters Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Nine Chapters Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7,400
Closed -$242K – 743
2015
Q3 		$242K Buy
+7,400
New +$315K 0.02% 776

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Nine Chapters Capital Management's ALDR Position: Q4 2015 in Review

Nine Chapters Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2015, closing a stake of 7,400 shares — an estimated $242K sold.

Nine Chapters Capital Management first reported a position in ALDR in Q3 2015 and held it in 1 quarter. The position peaked at $242K in Q3 2015. 134 funds tracked by Wall St. Rank hold ALDR as of Q4 2015.

  • Nine Chapters Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 7,400 Alder Biopharmaceuticals shares in Q4 2015, an estimated $242K.
  • Nine Chapters Capital Management first reported a position in Alder Biopharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Nine Chapters Capital Management's Alder Biopharmaceuticals position peaked at $242K in Q3 2015.
  • 134 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2015.

Based on Nine Chapters Capital Management's 13F filing for Q4 2015.